IRIS
DUMINUCO, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 732
AS - Asia 693
EU - Europa 633
AF - Africa 113
SA - Sud America 91
OC - Oceania 4
Totale 2.266
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 711
IT - Italia 477
SG - Singapore 340
CN - Cina 230
CI - Costa d'Avorio 82
KR - Corea 81
BR - Brasile 80
IE - Irlanda 51
FI - Finlandia 24
SN - Senegal 20
DE - Germania 14
IN - India 14
MX - Messico 9
UA - Ucraina 9
BE - Belgio 8
CA - Canada 8
GB - Regno Unito 8
CZ - Repubblica Ceca 7
FR - Francia 7
HK - Hong Kong 7
NL - Olanda 7
BD - Bangladesh 6
RU - Federazione Russa 5
SE - Svezia 5
AU - Australia 4
IQ - Iraq 4
NG - Nigeria 4
ZA - Sudafrica 4
AR - Argentina 3
ES - Italia 3
PL - Polonia 3
TR - Turchia 3
VE - Venezuela 3
VN - Vietnam 3
BO - Bolivia 2
JP - Giappone 2
KE - Kenya 2
PK - Pakistan 2
AL - Albania 1
CH - Svizzera 1
CO - Colombia 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
OM - Oman 1
PT - Portogallo 1
PY - Paraguay 1
SC - Seychelles 1
SI - Slovenia 1
TT - Trinidad e Tobago 1
Totale 2.266
Salva come PNG Salva come JPEG
Città #
Singapore 242
Santa Clara 232
Hefei 145
Chicago 114
Abidjan 82
Seoul 81
Catania 76
Ashburn 58
Dublin 49
Civitanova Marche 48
Chandler 43
Boardman 38
Rome 37
Beijing 36
Milan 29
Palermo 27
Dakar 20
Los Angeles 17
Florence 12
Bari 11
Lappeenranta 10
Helsinki 9
Misterbianco 9
Bronte 8
Brussels 8
Messina 8
Munich 8
Turin 8
Hong Kong 7
Cambridge 6
Lawrence 6
Washington 6
Cassano delle Murge 5
Chennai 5
Naples 5
Piazzola Sul Brenta 5
Rio de Janeiro 5
San Giovanni la Punta 5
Seattle 5
Turku 5
Abuja 4
Amsterdam 4
Belo Horizonte 4
Boston 4
Brno 4
Frankfurt am Main 4
Genoa 4
Mexico City 4
Paris 4
San Francisco 4
Aci Sant'Antonio 3
Atlanta 3
Johannesburg 3
Lamezia Terme 3
Melbourne 3
New York 3
Olomouc 3
Piacenza 3
Pozzallo 3
Santa Venerina 3
Warsaw 3
Örebro 3
Acireale 2
Ancona 2
Andover 2
Annapolis 2
Bologna 2
Campinas 2
Can Tho 2
Caselle Torinese 2
Cernusco sul Naviglio 2
Cornaredo 2
Council Bluffs 2
Curitiba 2
Galloway 2
Kochi 2
Lonigo 2
Mascalucia 2
Melilli 2
Montreal 2
Nairobi 2
Orvieto 2
Paternò 2
Pedara 2
Pirenópolis 2
Praia Grande 2
Ribeirão Preto 2
Santa Maria 2
Santos 2
Stockholm 2
São Paulo 2
Tokyo 2
Trecastagni 2
Valencia 2
Veracruz 2
Aci Castello 1
Aci Catena 1
Afogados da Ingazeira 1
Ankara 1
Aragona 1
Totale 1.677
Salva come PNG Salva come JPEG
Nome #
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases 96
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance 94
ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis 92
Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the MPL Gene: Two Case Reports 81
Targeted Metabolomics Highlights Dramatic Antioxidant Depletion, Increased Oxidative/Nitrosative Stress and Altered Purine and Pyrimidine Concentrations in Serum of Primary Myelofibrosis Patients 78
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab 76
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database 73
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project 71
Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology 70
Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field 69
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine 68
Saprochete capitata: Emerging Infections from Uncommon Microorganisms in Hematological Diseases 67
MacroH2A1.1 as a crossroad between epigenetics, inflammation and metabolism of mesenchymal stromal cells in myelodysplastic syndromes 63
Relapse of immune-mediated thrombotic thrombocytopenic purpura following mRNA COVID-19 vaccination: a prospective cohort study 60
Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future 60
Engagement of Mesenchymal Stromal Cells in the Remodeling of the Bone Marrow Microenvironment in Hematological Cancers 59
Hemophagocytic Syndrome in a Patient with ALL: Morphology Still Matters 58
Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting 57
Renal extramedullary hematopoiesis as an epiphenomenon of bone marrow dysfunction in a patient with primary myelofibrosis: A rare case report 56
A case of high-risk AML in a patient with advanced systemic mastocytosis 55
VEXAS-like syndrome: a potential new entity? 55
Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients 53
Role of Serum Free Light Chain Assay in Relapsed/Refractory Multiple Myeloma. A Real-Life Unicentric Retrospective Study 52
Immune Response and Breakthrough Infection Risk After SARS-CoV-2 Vaccines in Patients with Hemoglobinopathy: A Single Center Experience 51
Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes 49
Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data 47
AIPSS-MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib 47
Multicentric Castleman disease and concurrent hematological disorders: the occurrence of plasmacytoma and the hypotheses arising from literature's review 46
Therapeutic innovation for multi-resistant candidemics: synergy of isavuconazole and caspofungin association 46
The pharmacotherapeutic management of patients with myelofibrosis: looking beyond JAK inhibitors 45
Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions 45
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy 43
Lactate accumulation promotes immunosuppression and fibrotic transformation of bone marrow microenvironment in myelofibrosis 38
Myelofibrosis: In Search for BETter Targeted Therapies 34
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases 33
Transient Leukemoid Reaction from T-Cell Large Granular Lymphocytes Post Autologous Stem Cell Transplant in a Patient Affected by Hodgkin Lymphoma 33
Emergencies in Hematology: Why, When and How I Treat? 31
Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host Disease 31
Monocyte-to-platelets ratio (MPR) at diagnosis is associated with inferior progression-free survival in patients with mantle cell lymphoma: a multi-center real-life survey 28
Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasms 21
Occurrence of lymphoproliferative disorders during ruxolitinib treatment: May fedratinib be the turning point? 21
Chemotherapy extravasation: diagnosis, prevention and management 19
Emerging Therapeutic Approaches for Anemia in Myelofibrosis 17
Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World Study 15
Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib 12
Totale 2.315
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.014
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.014
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202252 0 0 0 0 6 4 3 1 6 14 5 13
2022/2023230 7 15 5 12 12 20 7 43 51 14 34 10
2023/2024474 26 60 22 55 13 88 33 36 6 17 80 38
2024/20251.189 16 174 41 114 190 121 60 45 71 85 123 149
2025/2026370 226 144 0 0 0 0 0 0 0 0 0 0
Totale 2.315